Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant and Granisetron for RINV Prophylaxis
NCT01183481Phase 2Terminated
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Jan 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aprepitant in radiation-induced nausea and vomiting (RINV), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Proportion of Patients Experiencing no Vomiting and no Nausea, Without Use of Any Rescue Antiemetic Medication(s), From Days 2-10 Following the Radiation Therapy. Started Jan 2011; status: terminated.
02
Drugs
aprepitant
03
Conditions
radiation-induced nausea and vomiting (RINV)
Beyond the preview
Go deeper on NCT01183481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01183481.